Complicated urinary tract infections (cUTIs) are severe infections affecting the urinary system, often associated with structural abnormalities or underlying health conditions. Globally, UTIs impact over 150 million people annually, with cUTIs accounting for a significant portion due to their complexity and resistance to standard treatments. The rising prevalence of antibiotic-resistant bacteria is driving the demand for more effective therapies. In response, pharmaceutical companies are focusing on the development of advanced antibiotics and complicated urinary tract infections therapeutic products. Recent innovations, such as new drug candidates like Cefiderocol and Fosfomycin, indicate robust growth in the pipeline in the coming years.
Major companies involved in the complicated urinary tract infections pipeline drugs market include Allecra, Jiangsu HengRui Medicine Co., Ltd., and others.
Leading drugs currently in the pipeline include Imipenem/Cilastatin and XNW4107 Combination, Cefepime and Enmetazobactam Combination, and others.
Increasing antibiotic resistance, growing investment in novel therapies, and rising demand for effective treatments are propelling the growth of the complicated urinary tract infection drug pipeline.
The Complicated Urinary Tract Infections Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into complicated urinary tract infections therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for complicated urinary tract infections. The complicated urinary tract infections report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The complicated urinary tract infections pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with complicated urinary tract infections treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to complicated urinary tract infections.
Complicated urinary tract infections (cUTIs) are severe infections that affect the bladder, kidneys, or urethra. They often arise due to structural abnormalities, the use of urinary catheters, or underlying health conditions such as diabetes. These infections are frequently caused by antibiotic-resistant bacteria, which makes them more challenging to treat and increases the risk of recurrence and complications if not managed properly.
Complicated urinary tract infections treatment involves broad-spectrum antibiotics, which are often administered intravenously in severe cases. Commonly used medications include Carbapenems, Cefiderocol, and Fosfomycin. It is essential to implement personalized therapies based on bacterial culture and sensitivity tests. New drug candidates and innovative treatments are being developed to address antibiotic resistance and enhance patient outcomes. Early diagnosis and targeted treatment are crucial for effective management.
Globally, urinary tract infections (UTIs) affect over 150 million people annually, making them one of the most common bacterial infections. In the United States, complicated UTIs account for over 626,000 hospitals admissions each year, representing approximately 1.8% of all hospitalizations. In the United Kingdom, around half of all women experience a UTI, while in India, UTI prevalence in women ranges from 3.14% to 19.87%, highlighting the significant disease burden.
This section of the report covers the analysis of complicated urinary tract infections drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total complicated urinary tract infections clinical trials.
The drug molecule categories covered under the complicated urinary tract infections pipeline analysis include small molecules, monoclonal antibodies, peptides, beta-lactamase inhibitors, nanoparticles, others. The complicated urinary tract infections report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for complicated urinary tract infections.
The EMR report for the complicated urinary tract infections drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed complicated urinary tract infections therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in complicated urinary tract infections clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for complicated urinary tract infections. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of complicated urinary tract infections drug candidates.
Imipenem/Cilastatin/XNW4107, sponsored by Evopoint Biosciences Inc., is currently undergoing a Phase 3 study. This study aims to evaluate the efficacy and safety of the drug compared to meropenem in hospitalized adults with complicated urinary tract infections (cUTIs). XNW4107 (Funobactam) is a novel serine β-lactamase inhibitor that enhances the activity of carbapenems against resistant bacterial strains such as Acinetobacter baumannii and Klebsiella pneumoniae.
Cefepime-enmetazobactam, developed by Allecra, is currently being studied in a Phase 2 trial to a...
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Complicated Urinary Tract Infections Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for complicated urinary tract infections. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into complicated urinary tract infections collaborations, regulatory environments, and potential growth opportunities.
Uncomplicated Urinary Tract Infection Epidemiology Forecast
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share